$9.2 million in revenue, raises full-year revenue guidance
225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end
645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024
BOSTON (November 6, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Read more.